SAPIRSTEIN JAMES 4
4 · First Wave BioPharma, Inc. · Filed Jan 3, 2024
Insider Transaction Report
Form 4
SAPIRSTEIN JAMES
DirectorPRESIDENT AND CEO
Transactions
- Award
Common Stock
2024-01-02+20,000→ 39,332 total - Award
Common Stock
2023-12-29+17,660→ 19,332 total
Footnotes (3)
- [F1]On December 29, 2023, the Reporting Person was granted 17,660 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest upon closing of the Issuer's proposed acquisition of ImmunogenX, Inc.
- [F2]On January 2, 2024, the Reporting Person was granted 20,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.
- [F3]Includes unvested RSUs.